APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuraminidase Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neuraminidase Inhibitor Market Outlook and Growth Opportunities 2026

31 December 2025196 pages

Choose your research edition.

Industry ResearchNeuraminidase Inhibitor Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuraminidase Inhibitor Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Neuraminidase Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuraminidase Inhibitor Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuraminidase Inhibitor Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Neuraminidase Inhibitor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neuraminidase Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuraminidase Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuraminidase Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neuraminidase Inhibitor market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neuraminidase Inhibitor market include GlaxoSmithKline, Gilead Sciences, F. Hoffman-La Roche, Daiichi Sankyo and BioCryst, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neuraminidase Inhibitor market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuraminidase Inhibitor and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuraminidase Inhibitor sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuraminidase Inhibitor market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuraminidase Inhibitor Segment by Company

GlaxoSmithKline

Gilead Sciences

F. Hoffman-La Roche

Daiichi Sankyo

BioCryst

Neuraminidase Inhibitor Segment by Type

Oseltamivir

Laninamivir

Peramivir

Zanamivir

Neuraminidase Inhibitor Segment by Application

Hospital Pharmacies

Drug Stores

Retail Stores

Others

Neuraminidase Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Neuraminidase Inhibitor status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neuraminidase Inhibitor market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neuraminidase Inhibitor significant trends, drivers, influence factors in global and regions.

6. To analyze Neuraminidase Inhibitor competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuraminidase Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuraminidase Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuraminidase Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neuraminidase Inhibitor market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuraminidase Inhibitor industry.

Chapter 3: Detailed analysis of Neuraminidase Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neuraminidase Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neuraminidase Inhibitor in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neuraminidase Inhibitor Industry Trends Table 2. Neuraminidase Inhibitor Industry Drivers Table 3. Neuraminidase Inhibitor Industry Opportunities and Challenges Table 4. Neuraminidase Inhibitor Industry Restraints Table 5. Global Neuraminidase Inhibitor Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neuraminidase Inhibitor Revenue Share by Company (2021-2026) Table 7. Global Neuraminidase Inhibitor Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Neuraminidase Inhibitor Sales Volume Share by Company (2021-2026) Table 9. Global Neuraminidase Inhibitor Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Neuraminidase Inhibitor Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neuraminidase Inhibitor Key Company Manufacturing Base & Headquarters Table 12. Global Neuraminidase Inhibitor Company, Product Type & Application Table 13. Global Neuraminidase Inhibitor Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neuraminidase Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oseltamivir Table 18. Significant Companies of Laninamivir Table 19. Significant Companies of Peramivir Table 20. Significant Companies of Zanamivir Table 21. Global Neuraminidase Inhibitor Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Neuraminidase Inhibitor Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Neuraminidase Inhibitor Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Neuraminidase Inhibitor Sales Volume Share by Type (2021-2026) Table 25. Global Neuraminidase Inhibitor Sales Volume Share by Type (2027-2032) Table 26. Global Neuraminidase Inhibitor Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Neuraminidase Inhibitor Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Neuraminidase Inhibitor Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Neuraminidase Inhibitor Sales Value Share by Type (2021-2026) Table 30. Global Neuraminidase Inhibitor Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Pharmacies Table 32. Significant Companies of Drug Stores Table 33. Significant Companies of Retail Stores Table 34. Significant Companies of Others Table 35. Global Neuraminidase Inhibitor Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Neuraminidase Inhibitor Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Neuraminidase Inhibitor Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Neuraminidase Inhibitor Sales Volume Share by Application (2021-2026) Table 39. Global Neuraminidase Inhibitor Sales Volume Share by Application (2027-2032) Table 40. Global Neuraminidase Inhibitor Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Neuraminidase Inhibitor Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Neuraminidase Inhibitor Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Neuraminidase Inhibitor Sales Value Share by Application (2021-2026) Table 44. Global Neuraminidase Inhibitor Sales Value Share by Application (2027-2032) Table 45. Global Neuraminidase Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Neuraminidase Inhibitor Sales by Region (2021-2026) & (K Units) Table 47. Global Neuraminidase Inhibitor Sales Market Share by Region (2021-2026) Table 48. Global Neuraminidase Inhibitor Sales by Region (2027-2032) & (K Units) Table 49. Global Neuraminidase Inhibitor Sales Market Share by Region (2027-2032) Table 50. Global Neuraminidase Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Neuraminidase Inhibitor Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Neuraminidase Inhibitor Sales Value Share by Region (2021-2026) Table 53. Global Neuraminidase Inhibitor Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Neuraminidase Inhibitor Sales Value Share by Region (2027-2032) Table 55. Global Neuraminidase Inhibitor Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Neuraminidase Inhibitor Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Neuraminidase Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Neuraminidase Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Neuraminidase Inhibitor Sales by Country (2021-2026) & (K Units) Table 60. Global Neuraminidase Inhibitor Sales Market Share by Country (2021-2026) Table 61. Global Neuraminidase Inhibitor Sales by Country (2027-2032) & (K Units) Table 62. Global Neuraminidase Inhibitor Sales Market Share by Country (2027-2032) Table 63. Global Neuraminidase Inhibitor Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Neuraminidase Inhibitor Sales Value Market Share by Country (2021-2026) Table 65. Global Neuraminidase Inhibitor Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Neuraminidase Inhibitor Sales Value Market Share by Country (2027-2032) Table 67. GlaxoSmithKline Company Information Table 68. GlaxoSmithKline Business Overview Table 69. GlaxoSmithKline Neuraminidase Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. GlaxoSmithKline Neuraminidase Inhibitor Product Portfolio Table 71. GlaxoSmithKline Recent Development Table 72. Gilead Sciences Company Information Table 73. Gilead Sciences Business Overview Table 74. Gilead Sciences Neuraminidase Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Gilead Sciences Neuraminidase Inhibitor Product Portfolio Table 76. Gilead Sciences Recent Development Table 77. F. Hoffman-La Roche Company Information Table 78. F. Hoffman-La Roche Business Overview Table 79. F. Hoffman-La Roche Neuraminidase Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. F. Hoffman-La Roche Neuraminidase Inhibitor Product Portfolio Table 81. F. Hoffman-La Roche Recent Development Table 82. Daiichi Sankyo Company Information Table 83. Daiichi Sankyo Business Overview Table 84. Daiichi Sankyo Neuraminidase Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Daiichi Sankyo Neuraminidase Inhibitor Product Portfolio Table 86. Daiichi Sankyo Recent Development Table 87. BioCryst Company Information Table 88. BioCryst Business Overview Table 89. BioCryst Neuraminidase Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. BioCryst Neuraminidase Inhibitor Product Portfolio Table 91. BioCryst Recent Development Table 92. Key Raw Materials Table 93. Raw Materials Key Suppliers Table 94. Neuraminidase Inhibitor Distributors List Table 95. Neuraminidase Inhibitor Customers List Table 96. Research Programs/Design for This Report Table 97. Authors List of This Report Table 98. Secondary Sources Table 99. Primary Sources List of Figures Figure 1. Neuraminidase Inhibitor Product Image Figure 2. Global Neuraminidase Inhibitor Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuraminidase Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neuraminidase Inhibitor Sales (2021-2032) & (K Units) Figure 5. Global Neuraminidase Inhibitor Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Neuraminidase Inhibitor Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oseltamivir Image Figure 10. Laninamivir Image Figure 11. Peramivir Image Figure 12. Zanamivir Image Figure 13. Global Neuraminidase Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Neuraminidase Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Neuraminidase Inhibitor Sales Volume Share by Type (2021-2032) Figure 16. Global Neuraminidase Inhibitor Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Neuraminidase Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Neuraminidase Inhibitor Sales Value Share by Type (2021-2032) Figure 19. Hospital Pharmacies Image Figure 20. Drug Stores Image Figure 21. Retail Stores Image Figure 22. Others Image Figure 23. Global Neuraminidase Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Neuraminidase Inhibitor Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Neuraminidase Inhibitor Sales Volume Share by Application (2021-2032) Figure 26. Global Neuraminidase Inhibitor Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Neuraminidase Inhibitor Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Neuraminidase Inhibitor Sales Value Share by Application (2021-2032) Figure 29. Global Neuraminidase Inhibitor Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Neuraminidase Inhibitor Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Neuraminidase Inhibitor Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Neuraminidase Inhibitor Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Neuraminidase Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 34. North America Neuraminidase Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Neuraminidase Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Neuraminidase Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Neuraminidase Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Neuraminidase Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Neuraminidase Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 40. South America Neuraminidase Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Neuraminidase Inhibitor Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Neuraminidase Inhibitor Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Neuraminidase Inhibitor Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Neuraminidase Inhibitor Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Oseltamivir
  • Laninamivir
  • Peramivir
  • Zanamivir
Applications
  • Hospital Pharmacies
  • Drug Stores
  • Retail Stores
  • Others
Companies covered
  • GlaxoSmithKline
  • Gilead Sciences
  • F. Hoffman-La Roche
  • Daiichi Sankyo
  • BioCryst

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neuraminidase Inhibitor Sales Value (2021-2032)
  4. 1.2.2 Global Neuraminidase Inhibitor Sales Volume (2021-2032)
  5. 1.2.3 Global Neuraminidase Inhibitor Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neuraminidase Inhibitor Market Dynamics
  1. 2.1 Neuraminidase Inhibitor Industry Trends
  2. 2.2 Neuraminidase Inhibitor Industry Drivers
  3. 2.3 Neuraminidase Inhibitor Industry Opportunities and Challenges
  4. 2.4 Neuraminidase Inhibitor Industry Restraints
3 Neuraminidase Inhibitor Market by Company
  1. 3.1 Global Neuraminidase Inhibitor Company Revenue Ranking in 2025
  2. 3.2 Global Neuraminidase Inhibitor Revenue by Company (2021-2026)
  3. 3.3 Global Neuraminidase Inhibitor Sales Volume by Company (2021-2026)
  4. 3.4 Global Neuraminidase Inhibitor Average Price by Company (2021-2026)
  5. 3.5 Global Neuraminidase Inhibitor Company Ranking (2024-2026)
  6. 3.6 Global Neuraminidase Inhibitor Company Manufacturing Base and Headquarters
  7. 3.7 Global Neuraminidase Inhibitor Company Product Type and Application
  8. 3.8 Global Neuraminidase Inhibitor Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neuraminidase Inhibitor Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neuraminidase Inhibitor Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neuraminidase Inhibitor Market by Type
  1. 4.1 Neuraminidase Inhibitor Type Introduction
  2. 4.1.1 Oseltamivir
  3. 4.1.2 Laninamivir
  4. 4.1.3 Peramivir
  5. 4.1.4 Zanamivir
  6. 4.2 Global Neuraminidase Inhibitor Sales Volume by Type
  7. 4.2.1 Global Neuraminidase Inhibitor Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Neuraminidase Inhibitor Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Neuraminidase Inhibitor Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Neuraminidase Inhibitor Sales Value by Type
  11. 4.3.1 Global Neuraminidase Inhibitor Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Neuraminidase Inhibitor Sales Value by Type (2021-2032)
  13. 4.3.3 Global Neuraminidase Inhibitor Sales Value Share by Type (2021-2032)
5 Neuraminidase Inhibitor Market by Application
  1. 5.1 Neuraminidase Inhibitor Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Drug Stores
  4. 5.1.3 Retail Stores
  5. 5.1.4 Others
  6. 5.2 Global Neuraminidase Inhibitor Sales Volume by Application
  7. 5.2.1 Global Neuraminidase Inhibitor Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Neuraminidase Inhibitor Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Neuraminidase Inhibitor Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Neuraminidase Inhibitor Sales Value by Application
  11. 5.3.1 Global Neuraminidase Inhibitor Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Neuraminidase Inhibitor Sales Value by Application (2021-2032)
  13. 5.3.3 Global Neuraminidase Inhibitor Sales Value Share by Application (2021-2032)
6 Neuraminidase Inhibitor Regional Sales and Value Analysis
  1. 6.1 Global Neuraminidase Inhibitor Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuraminidase Inhibitor Sales by Region (2021-2032)
  3. 6.2.1 Global Neuraminidase Inhibitor Sales by Region: 2021-2026
  4. 6.2.2 Global Neuraminidase Inhibitor Sales by Region (2027-2032)
  5. 6.3 Global Neuraminidase Inhibitor Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neuraminidase Inhibitor Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neuraminidase Inhibitor Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neuraminidase Inhibitor Sales Value by Region (2027-2032)
  9. 6.5 Global Neuraminidase Inhibitor Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neuraminidase Inhibitor Sales Value (2021-2032)
  12. 6.6.2 North America Neuraminidase Inhibitor Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neuraminidase Inhibitor Sales Value (2021-2032)
  15. 6.7.2 Europe Neuraminidase Inhibitor Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neuraminidase Inhibitor Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neuraminidase Inhibitor Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neuraminidase Inhibitor Sales Value (2021-2032)
  21. 6.9.2 South America Neuraminidase Inhibitor Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neuraminidase Inhibitor Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neuraminidase Inhibitor Sales Value Share by Country, 2025 VS 2032
7 Neuraminidase Inhibitor Country-level Sales and Value Analysis
  1. 7.1 Global Neuraminidase Inhibitor Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neuraminidase Inhibitor Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neuraminidase Inhibitor Sales by Country (2021-2032)
  4. 7.3.1 Global Neuraminidase Inhibitor Sales by Country (2021-2026)
  5. 7.3.2 Global Neuraminidase Inhibitor Sales by Country (2027-2032)
  6. 7.4 Global Neuraminidase Inhibitor Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neuraminidase Inhibitor Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neuraminidase Inhibitor Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neuraminidase Inhibitor Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neuraminidase Inhibitor Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neuraminidase Inhibitor Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GlaxoSmithKline
  2. 8.1.1 GlaxoSmithKline Company Information
  3. 8.1.2 GlaxoSmithKline Business Overview
  4. 8.1.3 GlaxoSmithKline Neuraminidase Inhibitor Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GlaxoSmithKline Neuraminidase Inhibitor Product Portfolio
  6. 8.1.5 GlaxoSmithKline Recent Developments
  7. 8.2 Gilead Sciences
  8. 8.2.1 Gilead Sciences Company Information
  9. 8.2.2 Gilead Sciences Business Overview
  10. 8.2.3 Gilead Sciences Neuraminidase Inhibitor Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Gilead Sciences Neuraminidase Inhibitor Product Portfolio
  12. 8.2.5 Gilead Sciences Recent Developments
  13. 8.3 F. Hoffman-La Roche
  14. 8.3.1 F. Hoffman-La Roche Company Information
  15. 8.3.2 F. Hoffman-La Roche Business Overview
  16. 8.3.3 F. Hoffman-La Roche Neuraminidase Inhibitor Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 F. Hoffman-La Roche Neuraminidase Inhibitor Product Portfolio
  18. 8.3.5 F. Hoffman-La Roche Recent Developments
  19. 8.4 Daiichi Sankyo
  20. 8.4.1 Daiichi Sankyo Company Information
  21. 8.4.2 Daiichi Sankyo Business Overview
  22. 8.4.3 Daiichi Sankyo Neuraminidase Inhibitor Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Daiichi Sankyo Neuraminidase Inhibitor Product Portfolio
  24. 8.4.5 Daiichi Sankyo Recent Developments
  25. 8.5 BioCryst
  26. 8.5.1 BioCryst Company Information
  27. 8.5.2 BioCryst Business Overview
  28. 8.5.3 BioCryst Neuraminidase Inhibitor Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 BioCryst Neuraminidase Inhibitor Product Portfolio
  30. 8.5.5 BioCryst Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neuraminidase Inhibitor Value Chain Analysis
  2. 9.1.1 Neuraminidase Inhibitor Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neuraminidase Inhibitor Sales Mode & Process
  6. 9.2 Neuraminidase Inhibitor Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neuraminidase Inhibitor Distributors
  9. 9.2.3 Neuraminidase Inhibitor Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst